Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Aspirin use associated with age-related macular degeneration

  • Comment

Taking aspirin regularly can more than double the risk of wet age-related macular degeneration (AMD), a leading cause of blindness in older people, according to a 15-year study.

The researchers found a significant link between taking aspirin once or more per week and wet AMD that could not be explained by a history of heart disease or smoking.

Wet AMD is caused by the growth of abnormal blood vessels in the retina and leads to a progressive blurring of central vision.

The researchers, led by Dr Gerald Liew from the University of Sydney in Australia, followed over 2,000 regular and non-regular aspirin users for 15 years, comparing rates of wet AMD.

At five, 10 and 15 years rates of wet AMD among non-regular users were 0.8%, 1.6% and 3.7%, respectively, compared with rates of 1.9%, 7%, and 9.3% among regular users - defined as taking aspirin once or more per week.

The authors of the study, published in the journal JAMA Internal Medicine, said: “Currently, there is insufficient evidence to recommend changing clinical practice, except perhaps in patients with strong risk factors for neovascular AMD… in whom it may be appropriate to raise the potentially small risk of incident neovascular AMD with long-term aspirin therapy.”

However, they added that any decision on whether to stop aspirin treatment was “complex and needs to be individualised”.

Commenting on the findings, US experts Dr Sanjay Kaul and Dr George Diamond, from Cedars-Sinai Medical Center in Los Angeles, wrote in the journal: “From a purely science-of-medicine perspective, the strength of the evidence is not sufficiently robust to be clinically directive.”












































  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs